Jazz Pharmaceuticals ((JAZZ)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Study Overview: Jazz Pharmaceuticals is conducting a Phase 3 study titled A Randomized, Multicenter, Phase 3 Study of Zanidatamab in Combination With Chemotherapy With or Without Tislelizumab in Subjects With HER2-positive Unresectable Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma (GEA). The study aims to evaluate the safety and efficacy of zanidatamab, with or without tislelizumab, compared to trastuzumab in treating advanced HER2-positive stomach and esophageal cancers. This study is significant as it explores potentially more effective treatment options for these aggressive cancers.
Intervention/Treatment: The study tests zanidatamab, an investigational drug, in combination with chemotherapy drugs capecitabine, oxaliplatin, cisplatin, and 5-fluorouracil. Tislelizumab, an immunotherapy drug, is also tested in one of the experimental arms to assess its added benefit.
Study Design: This is a randomized, open-label, multicenter study with a parallel assignment. The primary purpose is treatment, and there is no masking involved, meaning both researchers and participants know which treatment is being administered.
Study Timeline: The study began on December 2, 2021, and is currently active but not recruiting new participants. The last update was submitted on July 29, 2025. These dates are crucial for tracking the study’s progress and anticipating when results might be available.
Market Implications: This study could significantly impact Jazz Pharmaceuticals’ stock performance if zanidatamab demonstrates superior efficacy over existing treatments. Positive results may enhance investor confidence and position Jazz Pharmaceuticals competitively within the oncology market, particularly against other companies developing HER2-targeted therapies.
The study is ongoing, with further details available on the ClinicalTrials portal.